Recent advances in pulmonary arterial hypertension

Area of Science:

• Cardiology
• Genetics
• Molecular Biology

Background:

• Pulmonary arterial hypertension (PAH) is a rare, severe condition characterized by high mortality, often due to right heart failure.
• Despite treatment advances, premature mortality remains a significant issue for PAH patients.
• PAH exhibits considerable genetic and molecular heterogeneity, necessitating deeper understanding for effective therapeutic development.

Purpose of the Study:

• To explore the genetic and molecular underpinnings of pulmonary arterial hypertension (PAH).
• To identify novel therapeutic targets by investigating the heterogeneity of PAH.
• To highlight the challenges in selecting and prioritizing drug targets for PAH.

Main Methods:

• Review of current literature on PAH genetics and molecular biology.
• Analysis of transcriptomic, proteomic, and metabolomic studies for PAH endophenotypes.
• Examination of genetic mutations, focusing on the BMPR2 gene and other identified genes.

Main Results:

• The BMPR2 gene is the most frequently implicated in both familial and non-familial PAH.
• Rare mutations in other genes also contribute to PAH development.
• Ongoing omics studies aim to define molecular endophenotypes.

Conclusions:

• Understanding PAH's genetic and molecular heterogeneity is essential for advancing treatment strategies.
• Numerous potential drug targets exist, but their selection and prioritization pose significant challenges.
• Further research into molecular pathways is critical to combatting right heart failure and improving PAH patient outcomes.